Business
Rocket Pharmaceuticals Announces Presentations Highlighting Three Lentiviral Gene Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting
—Updated clinical data to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD— CRANBURY, N.J.--(BUSINESS WIRE)--
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\n —Updated clinical data to be presented from ongoing Phase 2 registrational trials in LAD-I and FA and Phase 1 trial in PKD—\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces upcoming data presentations at the 63rd American Society of Hematology (ASH) Annual Meeting taking place virtually and in Atlanta, Georgia from December 11-14, 2021.\n\nPresentations will include updated clinical data from three of Rocket’s lentiviral vector (LVV)-based gene therapy programs. The presentations will highlight the Phase 1 global clinical trial of RP-L301 in Pyruvate Kinase Deficiency (PKD) and Phase 2 registrational trials of RP-L201 for Leukocyte Adhesion Deficiency-I (LAD-I) and RP-L102 for Fanconi Anemia (FA).\n\nDetails for Rocket’s oral presentation are as follows:\n\nTitle: Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients\nSession: 801. Gene Therapy: Basic, Translational and Clinical Studies\nPresenter: Ami Shah, MD, Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA\nDate: Sunday, December 12, 2021\nSession Time: 4:30 p.m. – 6:00 p.m. ET\nPresentation Time: 5:30 p.m. ET\nLocation: Georgia World Congress Center, B207-B208\nPublication Number: 563\n\nDetails for Rocket’s poster presentations are as follows:\n\nTitle: A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Interim Results\nSession: 801. Gene Therapies: Poster II\nPresenter: Elena Almarza, PhD, Senior Scientist, Rocket Pharmaceuticals\nDate: Sunday, December 12, 2021\nSession Time: 6:00 p.m. – 8:00 p.m. ET\nLocation: Georgia World Congress Center, Hall B5\nPublication Number: 2932\n\nTitle: Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials\nSession: 801. Gene Therapies: Poster III\nPresenter: Agnieszka Czechowicz, MD, PhD, Center for Definitive and Curative Medicine, Stanford University School of Medicine, Stanford, CA\nDate: Monday, December 13, 2021\nSession Time: 6:00 p.m. – 8:00 p.m. ET\nLocation: Georgia World Congress Center, Hall B5\nPublica...